RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental CAR-T therapy targets tough T-Cell cancers
Disease control Recruiting nowThis early study tests a new treatment called U69, which uses a patient's own immune cells modified to find and attack cancer cells in T-cell leukemia or lymphoma that has come back or not responded to other treatments. About 12 to 18 people aged 15 to 75 will receive the therapy…
Matched conditions: RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental 'Super-Universal' immune cells take on tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy called supCD7 CART cells in 12 adults with relapsed or refractory CD7-positive blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia). The cells are designed to target and kill cancer cells that carry…
Matched conditions: RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC